Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investor page, and a replay will be available for 30 days post-event. The company's management will discuss key developments and insights related to their kidney disease therapeutics pipeline.
- None.
- None.
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET.
A live webcast will be accessible on the Investor page of Travere’s website at ir.travere.com/events-presentations, and a replay will be available for up to 30 days following the event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
| Contact: | |
| Investors: 888-969-7879 IR@travere.com | Media: 888-969-7879 mediarelations@travere.com |
FAQ
When is Travere Therapeutics presenting at the H.C. Wainwright Kidney Conference?
Where can I watch the Travere Therapeutics presentation at the H.C. Wainwright Kidney Conference?
How long will the replay of Travere Therapeutics' presentation be available?
What is the stock symbol for Travere Therapeutics?
What will be discussed by Travere Therapeutics at the H.C. Wainwright Kidney Conference?
